Camp4 Therapeutics Corp. (CAMP) Insider Trading

Cluster buy

4 insiders bought $99k of their own stock in 29 days.

Open-market purchases by executives and directors between Aug 3 and Aug 31. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market

−$2.4M

5 buys · 4 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

4 / 2

executives and directors

Last open-market buy

Aug 2026

Aug 31, 2026

Get an email when CAMP's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 31	Kelly Gold Chief Financial Officer	Bought	10,000	$3.96	$40k	13%	Form 4
Aug 27	Andrew J. Schwab Director	SoldNo plan	400,000	$4.04	$1.62M	7.0%	Form 4
Aug 24	Andrew J. Schwab Director	SoldNo plan	10	$4.50	$45	<0.1%	Form 4
Aug 19 – 21	Andrew J. Schwab Director	SoldNo plan 3 parts	191,865	$4.59 average	$880k	3.3%	Form 4
Aug 19	Daniel Tardiff Chief Scientific Officer	SoldNo plan	1,738	$4.76	$8k	100%	Form 4
Aug 3	Richard A Young Director	Bought	16,378	$1.65	$27k	9.6%	Form 4
Aug 3	Yuri Maricich Chief Medical Officer	Bought	6,551	$1.65	$11k	108%	Form 4
Aug 3	Kelly Gold Chief Financial Officer	Bought	6,551	$1.65	$11k	9.7%	Form 4
Aug 3	Josh Mandel-Brehm Chief Executive Officer	Bought	6,551	$1.65	$11k	2.4%	Form 4
Sep 11, 2025	5AM Ventures Vii, L.p. Large holder	Bought	2,941,176	$1.53	$4.5M	100%	Form 4
Sep 11, 2025	Kelly Gold Chief Financial Officer	Bought	6,060	$1.65	$10k	9.8%	Form 4
Sep 11, 2025	Josh Mandel-Brehm Chief Executive Officer	Bought	6,060	$1.65	$10k	2.2%	Form 4
Sep 11, 2025	Yuri Maricich Chief Medical Officer	Bought	6,060	$1.65	$10k	New	Form 4
Sep 11, 2025	Richard A Young Director	Bought	15,151	$1.65	$25k	9.8%	Form 4
Sep 11, 2025	Polaris Management Co. Vii, L.l.c. Large holder	Bought 2 parts	1,307,189	$1.53 average	$2M	New	Form 4
Sep 11, 2025	Amir Nashat Director	Bought 2 parts	1,307,189	$1.53 average	$2M	New	Form 4

Aug 31
Kelly Gold
Chief Financial Officer · bought 10,000 at $3.96
$40k
13% of stake
Aug 27No plan
Andrew J. Schwab
Director · sold 400,000 at $4.04
$1.62M
7.0% of stake
Aug 24No plan
Andrew J. Schwab
Director · sold 10 at $4.50
$45
<0.1% of stake
Aug 19 – 21No plan
Andrew J. Schwab
Director · sold 191,865 at avg $4.59
$880k
3.3% of stake
Aug 19No plan
Daniel Tardiff
Chief Scientific Officer · sold 1,738 at $4.76
$8k
100% of stake
Aug 3
Richard A Young
Director · bought 16,378 at $1.65
$27k
9.6% of stake
Aug 3
Yuri Maricich
Chief Medical Officer · bought 6,551 at $1.65
$11k
108% of stake
Aug 3
Kelly Gold
Chief Financial Officer · bought 6,551 at $1.65
$11k
9.7% of stake
Aug 3
Josh Mandel-Brehm
Chief Executive Officer · bought 6,551 at $1.65
$11k
2.4% of stake
Sep 11, 2025
5AM Ventures Vii, L.p.
Large holder · bought 2,941,176 at $1.53
$4.5M
100% of stake
Sep 11, 2025
Kelly Gold
Chief Financial Officer · bought 6,060 at $1.65
$10k
9.8% of stake
Sep 11, 2025
Josh Mandel-Brehm
Chief Executive Officer · bought 6,060 at $1.65
$10k
2.2% of stake
Sep 11, 2025
Yuri Maricich
Chief Medical Officer · bought 6,060 at $1.65
$10k
New position
Sep 11, 2025
Richard A Young
Director · bought 15,151 at $1.65
$25k
9.8% of stake
Sep 11, 2025
Polaris Management Co. Vii, L.l.c.
Large holder · bought 1,307,189 at avg $1.53
$2M
New position
Sep 11, 2025
Amir Nashat
Director · bought 1,307,189 at avg $1.53
$2M
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CAMP, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

ATAIAtaiBeckley Inc.

PRPHProPhase Labs Inc.

CPHIChina Pharma Holdings Inc.

MRKRMarker Therapeutics, Inc.

ENSCEnsysce Biosciences Inc.

KYNBKyntra Bio, Inc.

BOLTBolt Biotherapeutics Inc.

RANIRani Therapeutics Holdings Inc.

Spot a number that looks wrong? Check it in CAMP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CAMP

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.